Marshall Wace, LLP Chemo Centryx, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $25.5 Million - $59.5 Million	-1,148,048 Reduced 97.38%	30,900 $1.6 Million
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $3.37 Million - $6.04 Million	-219,635 Reduced 15.7%	1,178,948 $29.2 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $12.7 Million - $22.3 Million	569,585 Added 68.71%	1,398,583 $35.1 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $15.2 Million - $33.6 Million	828,998 New	828,998 $30.2 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $5.61 Million - $7.46 Million	-121,003 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $4.2 Million - $7.09 Million	108,919 Added 901.35%	121,003 $6.96 Million
Q1 2020 May 15, 2020	SELL	$32.73 - $50.78 $1.32 Million - $2.04 Million	-40,186 Reduced 76.88%	12,084 $486,000
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $355,958 - $2.07 Million	52,270 New	52,270 $2.07 Million
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $1.1 Million - $1.97 Million	-132,410 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$10.01 - $13.89 $1.33 Million - $1.84 Million	132,410 New	132,410 $1.84 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.